Search
Displaying results 1111 to 1120 of 1203.
Myxobacteria set sail
So far, citizen scientists have provided HIPS with over 700 soil samples from Saarland and other areas of Germany. From these samples, just as many new myxobacteria and several new natural products have already been identified. Some of these show promising properties…
Shedding light on the number of undetected SARS-CoV-2 infections
Even though many infections with SARS-CoV-2 cause only mild cold symptoms or are asymptomatic, the high total number of infections necessitates effective protective measures to protect the most vulnerable groups from severe courses of the disease. To this end, it is…
COR-101 is Inhibiting the Emerging Delta Variant of SARS-CoV-2
In the first step, the researchers isolated the genetic information of immune cells, which are producing anti-SARS-CoV-2 antibodies, from blood samples from local convalescent COVID-19 patients. From the collected antibody genes, they constructed a phage display…
NFDI4Microbiota celebrates success in second round of NFDI calls
“In our vision of the future, microbiology researchers will easily be able to translate existing research data into a deep understanding of microbial species and their molecular-level interactions,” says the consortium’s spokesman, Professor Konrad Förstner from ZB MED…
Helmholtz researches holistic solutions for pandemic response
To deal with the Corona pandemic and its effects, we need scientific knowledge and solutions that go far beyond health research. The pandemic has revealed the stress limits of our critical infrastructures and dependencies on global supply chains. Helmholtz scientists…
CRISPR discovery from Würzburg paves the way for novel COVID testing method
Most conventional molecular diagnostics usually detect only a single disease-related biomarker. Great examples are the PCR tests currently used to diagnose COVID-19 by detecting a specific sequence from SARS-CoV-2. Such so-called singleplex methods provide reliable…
How well are we protected six months after infection or vaccination?
How long and how well does the human immune system remember an encounter with SARS-CoV-2 or an encounter with at least fragments of the virus, as is the case with vaccination? One year? Two years? And during that time, how well is one still protected from infection with…
iCAIR® consortium delivers first results on the way to inhalable drugs against SARS-CoV-2
While the first vaccines against SARS-CoV-2 have now been approved in Europe and other countries, drugs for specific and efficient treatment of COVID-19 have as yet only limited availability – but are urgently needed. Because of the typical long drug development…
New viruses, new challenges
Viruses are small particles - about 1000x smaller than human cells - that exploit their host's metabolism to replicate. There are many thousands of viruses circulating in the animal world that could spread to humans. SARS-CoV-2 has shown how quickly new viruses can…
World Tuberculosis Day 2021: New drugs for old bugs
The department Microbial Natural Products at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS), a joint site of Helmholtz Centre for Infection Research (HZI) with Saarland University, is exploring soil bacteria for new active substances to solve these…
